Know Cancer

forgot password

Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy

Phase 4
18 Years
Not Enrolling
Iron-Deficiency Anemia

Thank you

Trial Information

Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy

Inclusion Criteria:

- Subjects (male or female) aged ≥18, suffering from a newly diagnosed or
progressed/relapsed MM and scheduled to receive anti-myeloma treatment. Progression
is defined according to "Uniform Response Criteria for Multiple Myeloma"

- Subjects with progressed/relapsed MM should have had stable disease (during the last
6 months since prior treatment).

- Life expectancy at least 6 months.

- 8.5 g/dL ≤Hb ≤11 g/dL at time of randomisation.

- Iron-restricted erythropoiesis as defined:

- Stainable iron in bone marrow (BM) combined with transferrin saturation (TSAT)
≤20%, or

- where the evaluation of stainable iron in BM is not possible or available:

- ferritin >30 ng/mL (women) or >40 ng/mL (men), and

- TSAT ≤20%

- Females of child-bearing potential must have a negative urine pregnancy test at

- Before any study-specific procedure, the appropriate written informed consent must be

Exclusion Criteria:

- Any anaemia treatment within 4 weeks prior to randomisation (including red blood cell
transfusions, treatment with ESA or any oral/parenteral iron preparations).

- Anthracycline containing chemotherapy regimens.

- Subjects weighing <35 kg.

- Folate deficiency (serum-folate <4.5 nmol/L) and/or Vitamin B12 deficiency
(serum-cobalamin <145 pmol/L).

- Ongoing haemolysis defined as serum-haptoglobin <0.2 g/L.

- Known chronic renal failure, glomerular filtration rate <30 mL/min/m2.

- Recent (within last 4 weeks) significant bleeding/surgery, defined as drop in Hb of
≥2 g/dL.

- Clinically relevant active inflammatory disease other than MM (according to the
judgement of the Investigator).

- Clinically relevant ongoing infectious disease including known human immunodeficiency

- Serum ferritin >600 ng/mL.

- Ongoing significant neurological or psychiatric disorders including psychotic
disorders or dementia.

- Significant cardiovascular disease prior to study inclusion including myocardial
infarction within 12 months prior to study inclusion, congestive heart failure New
York Heart Association Grade III or IV, or poorly controlled hypertension according
to the judgment of the Investigator.

- Elevation of liver enzymes (aspartate aminotransferase, alanine aminotransferase)
over 3 times above the normal range or known acute hepatic disorder.

- Subject currently is enrolled in or has not yet completed at least 30 days since
ending other investigational device or drug study(ies), or subject is receiving other
investigational agent(s).

- Subject of child-bearing potential is evidently pregnant (e.g., positive human
chorionic gonadotropin test) or is breast feeding.

- Subject is not using adequate contraceptive precautions. Adequate contraceptive
precautions are defined as those which result in a low failure rate (i.e., less than
1% per year) when used consistently and correctly such as implants, injectables,
combined oral contraceptives, some intra-uterine devices, sexual abstinence or
vasectomised partner. Non-childbearing potential includes being surgically sterilised
at least 6 months prior to the study or post-menopausal, defined as amenorrhea for at
least 12 months.

- Subject has known sensitivity to any of the products to be administered during

- Subject will not be available for follow-up assessment.

- Subject has any kind of disorder that compromises the ability of the subject to give
written informed consent and/or to comply with study procedures.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Change in haemoglobin from baseline to Week 8

Outcome Time Frame:

week 8 post baseline

Safety Issue:


Principal Investigator

Katodritou Eirini, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Theagenion Hospital, Thessaloniki, Greece


France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:




Start Date:

March 2010

Completion Date:

October 2011

Related Keywords:

  • Iron-Deficiency Anemia
  • Anemia
  • Lymphoproliferative Disorders
  • Chemotherapy
  • ferric carboxymaltose
  • iron
  • Anemia
  • Multiple Myeloma
  • Neoplasms, Plasma Cell
  • Deficiency Diseases
  • Anemia, Iron-Deficiency